argenex (NASDAQ:ARGX) Upgraded to "Buy" at Deutsche Bank Aktiengesellschaft

argenex (NASDAQ:ARGX - Get Free Report) was upgraded by investment analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "buy" rating in a research note issued on Tuesday, Marketbeat.com reports.

A number of other analysts also recently weighed in on ARGX. Oppenheimer increased their price target on shares of argenex from $704.00 to $708.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Baird R W upgraded shares of argenex from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. JMP Securities set a $699.00 target price on shares of argenex in a research note on Wednesday, May 14th. Citigroup reaffirmed a "buy" rating on shares of argenex in a research report on Wednesday, May 21st. Finally, Wedbush reissued an "outperform" rating and issued a $715.00 target price on shares of argenex in a research report on Tuesday, June 24th. Nineteen equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $728.06.

argenex Stock Up 1.5%

NASDAQ:ARGX traded up $8.12 during mid-day trading on Tuesday, reaching $563.31. 364,107 shares of the company were exchanged, compared to its average volume of 333,129. argenex has a 12 month low of $457.42 and a 12 month high of $678.21. The company has a fifty day moving average of $570.86 and a 200 day moving average of $602.95. The stock has a market cap of $34.40 billion, a PE ratio of 34.75, a PEG ratio of 0.99 and a beta of 0.37.

argenex (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.26. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. argenex had a net margin of 40.20% and a return on equity of 16.15%. On average, equities research analysts anticipate that argenex will post 3.13 EPS for the current fiscal year.

Institutional Trading of argenex

Several institutional investors have recently added to or reduced their stakes in ARGX. GeoWealth Management LLC boosted its holdings in shares of argenex by 56.3% during the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after buying an additional 18 shares in the last quarter. Rakuten Securities Inc. increased its position in shares of argenex by 56.4% during the 1st quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock valued at $36,000 after purchasing an additional 22 shares during the last quarter. WPG Advisers LLC purchased a new stake in argenex in the 1st quarter worth about $37,000. FIL Ltd bought a new position in argenex in the 4th quarter worth about $38,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of argenex during the 4th quarter valued at about $38,000. 60.32% of the stock is currently owned by institutional investors.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.